ko	pathway	ratio_in_study	ratio_in_pop	p_value
ko05219	Bladder cancer	1/1	48/7206	0.00666111573692
ko05213	Endometrial cancer	1/1	62/7206	0.00860394116014
ko05221	Acute myeloid leukemia	1/1	63/7206	0.00874271440465
ko05223	Non-small cell lung cancer	1/1	66/7206	0.00915903413824
ko04730	Long-term depression	1/1	78/7206	0.0108243130725
ko05214	Glioma	1/1	79/7206	0.010963086317
ko05212	Pancreatic cancer	1/1	83/7206	0.0115181792951
ko05220	Chronic myeloid leukemia	1/1	85/7206	0.0117957257841
ko05218	Melanoma	1/1	85/7206	0.0117957257841
ko05210	Colorectal cancer	1/1	86/7206	0.0119344990286
ko05211	Renal cell carcinoma	1/1	96/7206	0.0133222314738
ko04650	Natural killer cell mediated cytotoxicity	1/1	97/7206	0.0134610047183
ko04720	Long-term potentiation	1/1	99/7206	0.0137385512073
ko04914	Progesterone-mediated oocyte maturation	1/1	104/7206	0.01443241743
ko01521	EGFR tyrosine kinase inhibitor resistance	1/1	106/7206	0.014709963919
ko04012	ErbB signaling pathway	1/1	109/7206	0.0151262836525
ko05215	Prostate cancer	1/1	111/7206	0.0154038301415
ko01522	Endocrine resistance	1/1	124/7206	0.0172078823203
ko04726	Serotonergic synapse	1/1	137/7206	0.019011934499
ko05160	Hepatitis C	1/1	153/7206	0.0212323064114
ko04270	Vascular smooth muscle contraction	1/1	154/7206	0.0213710796559
ko04068	FoxO signaling pathway	1/1	167/7206	0.0231751318347
ko04910	Insulin signaling pathway	1/1	172/7206	0.0238689980573
ko05224	Breast cancer	1/1	174/7206	0.0241465445463
ko05034	Alcoholism	1/1	238/7206	0.0330280321954
ko04810	Regulation of actin cytoskeleton	1/1	264/7206	0.0366361365529
ko05205	Proteoglycans in cancer	1/1	271/7206	0.0376075492647